Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway

References

• Brooks LRK, and Mias GI . Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention. Front Immunol. 2018 Jun 22;9:1366. doi:10.3389/fimmu.2018.01366. PMID: 29988379; PMCID: PMC6023974.
   Web of Science ®Google Scholar
• File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med. 2004;117(Suppl 3A):39S–9. doi:10.1016/j.amjmed.2004.07.007.
   PubMedGoogle Scholar
• Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Ag. 2008;32(3):199–206. doi:10.1016/j.ijantimicag.2008.01.021.
   PubMed Web of Science ®Google Scholar
• Winje BA, Vestrheim DF, White RA, Steens A. The risk of invasive Pneumococcal disease differs between risk groups in Norway following widespread use of the 13-valent pneumococcal vaccine in children. Microorganisms. 2021;9(8):1774. doi:10.3390/microorganisms9081774.
   PubMed Web of Science ®Google Scholar
• Pneumokokkvaksine - veileder for helsepersonell [Internet]; [accessed 2022 Mar 27]. https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/pneumokokkvaksinasjon—veileder-fo/.
   Google Scholar
• Folkehelseinstituttet. Vaksinasjonsveilederen for Helsepsersonell (Vaskinasjonsboka) [Internet]. Oslo: Folkehelseinstituttet; 2015 [accessed 2022 Mar 1]. https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/.
   Google Scholar
• The “blue prescription” regulation [Internet]; [accessed 2022 March 27]. https://lovdata.no/dokument/SF/forskrift/2007-06-28-814.
   Google Scholar
• Executive order on free pneumococcal vaccination for certain groups of persons. BEK nr 395 af 07/04/2020 [Internet]. The Danish Ministry of Health; [accessed 2022 Mar 1]. https://www.retsinformation.dk/eli/lta/2020/395.
   Google Scholar
• Hälsoekonomisk utvärdering av pneumokockvaccination som ett särskilt vaccinationsprogram för personer 75 år och äldre. Public Health Agency of Sweden [Internet]; [accessed 2022 Mar 1]. https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/h/halsoekonomisk-utvardering-av-pneumokockvaccination-som-ett-sarskilt-vaccinationsprogram-for-personer-75-ar-och-aldre/.
   Google Scholar
• Wolff E, Storsaeter J, Ortqvist A, Naucler P, Larsson S, Lepp T, Roth A. Cost-effectiveness of pneumococcal vaccination for elderly in Sweden. Vaccine. 2020;38(32):4988–4995. doi:10.1016/j.vaccine.2020.05.072.
   PubMed Web of Science ®Google Scholar
• Efficacy and effectiveness of pneumococcal vaccination in adults – a second update of the literature. [Effekt av pneumokokkvaksine hos eldre] Report 2019 [Internet]. Oslo: Norwegian Institute of Public Health; 2022. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2022/efficacy-and-effectiveness-of-pneumococcal-vaccination-in-adults.pdf.
   Google Scholar
• Norwegian Medicines Agency. Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals [Internet]. Oslo (Norway): Norwegian Medicines Agency; 2018 [accessed 2022 March 1]. https://legemiddelverket.no/Documents/English/Public%20funding%20and%20pricing/Documentation%20for%20STA/Guidelines%2018.10.2021.pdf.
   Google Scholar
• Nymark L, and Vassall A. A comprehensive framework for considering additional unintended consequences in economic evaluation. Cost Effect Resour Alloc. 2020;18:27. https://doi.org/10.1186/s12962-020-00218-8.
   Google Scholar
• Holter JC, Muller F, Bjorang O, Samdal HH, Marthinsen JB, Jenum PA, Ueland T, Frøland SS, Aukrust P, Husebye E, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis. 2015;15(1):64. doi:10.1186/s12879-015-0803-5.
   PubMedGoogle Scholar
• Roysted W, Simonsen O, Jenkins A, Sarjomaa M, Svendsen MV, Ragnhildstveit E, Tveten Y, Kanestrøm A, Waage H, Ringstad J, et al. Aetiology and risk factors of community-acquired pneumonia in hospitalized patients in Norway. Clin Respir J. 2016;10(6):756–764. doi:10.1111/crj.12283.
   PubMed Web of Science ®Google Scholar
• Naucler P, Henriques-Normark B, Hedlund J, Galanis I, Granath F, Ortqvist A. The changing epidemiology of community-acquired pneumonia: nationwide register-based study in Sweden. J Intern Med. 2019;286(6):689–701. doi:10.1111/joim.12956.
   PubMed Web of Science ®Google Scholar
• Ieven M, Coenen S, Loens K, Lammens C, Coenjaerts F, Vanderstraeten A, Henriques-Normark B, Crook D, Huygen K, Butler CC, et al. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. Clin Microbiol Infect. 2018;24(11):1158–1163. doi:10.1016/j.cmi.2018.02.004.
   PubMed Web of Science ®Google Scholar
• Lyngstad TM, Kristoffersen AB, Winje BA, Steens A. Estimation of the incidence of hospitalisation for non-invasive pneumococcal pneumonia in the Norwegian population aged 50 years and older. Epidemiol Infect. 2022;150. doi:10.1017/S0950268822000607.
   Web of Science ®Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, et al. Serotype-Specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against Pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–321. doi:10.1016/S1473-3099(17)30049-X.
   PubMed Web of Science ®Google Scholar
• Norwegian Instiute of Public Health. Norwegian surveillance system for communicable diseases [Internet]. Oslo (Norway): Norwegian Instiute of Public Health [accessed 2022 Mar 1]. http://www.msis.no/.
   Google Scholar
• Årsrapport for 2017. Invasive infeksjoner [Internet]. Oslo (Norway): Norwegian Instiute of Public Health; 2018. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2018/arsrapport-invasive-infeksjoner-2017.pdf.
   Google Scholar
• Kraicer-Melamed H, O’-Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine. 2016;34(13):1540–1550. doi:10.1016/j.vaccine.2016.02.024.
   PubMed Web of Science ®Google Scholar
• Kim JH, Chun BC, Song JY, Kim HY, Bae IG, Kim DM, Choi YH, Jun YH, Choi WS, Kang SH, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study. Vaccine. 2019;37(21):2797–2804. doi:10.1016/j.vaccine.2019.04.017.
   PubMed Web of Science ®Google Scholar
• Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, Andrews NJ. Effectiveness of 23-valent polysaccharide Pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClin Med. 2018;6:42–50. doi:10.1016/j.eclinm.2018.12.007.
   PubMedGoogle Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJ. The impact of age on the efficacy of 13-valent Pneumococcal conjugate vaccine in elderly. Clin Infect Dis. 2015;61(12):1835–1838. doi:10.1093/cid/civ686.
   PubMed Web of Science ®Google Scholar
• Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, van Deursen AMM, van der Ende A, Grobbee DE, Sanders EAM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407–1416. doi:10.1183/13993003.00325-2015.
   PubMed Web of Science ®Google Scholar
• Burström K, and Rehnberg C. Hälsorelaterad livskvalitet i Stockholms län 2002- 2006; Rapport 2006:1. Enheten för Socialmedisin och Hälsoekonomi. Centrum för Folkhälsa. FORUM för kunnskap og gemensam utvikling. Stockholm, Sweden: Stockholm läns landsting, 2006.
   Google Scholar
• Blommaert A, Hanquet G, Willem L, Theeten H, Thiry N, Bilcke J, Verhaegen J, Beutels P.Use of pneumococcal vaccines in the elderly: an economic evaluation – Synthesis. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2016. KCE Reports 274Cs. D/2016/.Please see the link below on page 45: https://kce.fgov.be/sites/default/files/2021-11/KCE_274C_Short-Report_Pneumococcal.pdf, https://kce.fgov.be/sites/default/files/2021-11/KCE_274C_Short-Report_Pneumococcal.pdf.
   Google Scholar
• Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review. BMC Infect Dis. 2016;16(1):711. doi:10.1186/s12879-016-2040-y.
   PubMed Web of Science ®Google Scholar
• Jiménez E, Torkilseng EB, Klemp M Cost-Effectiveness of HPV vaccination of boys aged 12 in a Norwegian setting. Report from Kunnskapssenteret no. 2−2015. Oslo: Norwegian Knowledge Centre for the Health Services; 2015.
   Google Scholar
• Jiménez E, Wisløff T, Klemp M Cost-Effectiveness of a HPV vaccination catch-up program for females aged 26 years or younger in a Norwegian setting. Report from Kunnskapssenteret no. 5−2012. Oslo: Norwegian Knowledge Centre for the Health Services; 2012.
   Google Scholar
• Berg AS, Furuseth E, Greve-Isdahl M, Grosvold IW, Næss LS, Nøkleby H, Stålkrantz J, Tunheim G, Wisløff T, Wolden B, et al. Kikhostevaksine til gravide – aktuelt for Norge? [Maternal Immunization against Pertussis. Evaluation for Norway] Rapport 2019. Oslo: Folkehelseinstituttet.
   Google Scholar
• Norwegian Medicines Agency. Oslo (Norway) [Internet]; [accessed 2022 March 1]. https://legemiddelverket.no/english.
   Google Scholar
• Norwegian Medicines Agency. Oslo (Norway) [Internet]; [accessed 2022 Mar 27]. https://legemiddelverket.no/offentlig-finansiering/maksimalpris#oversikt-over-maksimalpriser.
   Google Scholar
• Watle SV, Naess LM, Tunheim G, Caugant DA, Wisloff T. Cost-Effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine. Hum Vaccin Immunother. 2021;17(8):2777–2787. doi:10.1080/21645515.2021.1880209.
   PubMed Web of Science ®Google Scholar
• Norwegian Medical Association. General practitioner fees list. Collective Agreement; 2021- 2022 [Internet]; [ accessed 2022 Mar 1]. https://normaltariffen.legeforeningen.no/asset/pdf/Fastlegetariffen-2021-2022.pdf.
   Google Scholar
• Norwegian: (ISF_regulations_2022_DRGlist somatic). Norwegian Directorate of Health [Internet]; 2022 [ accessed 2022 Mar 1]. https://www.helsedirektoratet.no/tema/finansiering/innsatsstyrt-finansiering-og-drg-systemet/innsatsstyrt-finansiering-isf/ISF-regelverk%202022.pdf/_/attachment/inline/f7f190ab-33fc-4e07-9d36-fd5fc9e4e17e:9d97d72b2acf5c719d19cde034b6174007b84923/ISF-regelverk%202022.pdf.
   Google Scholar
• Antibiotikabruk i primærhelsetjenesten. Oslo (Norway) [Internet]; [accessed 2022 Mar 27]. https://www.antibiotikaiallmennpraksis.no/index.php?action=showtopic&topic=f6000288c623ddf6aa4c.
   Google Scholar
• NORM/NORM-VET. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo. 2019 ISSN:1502-2307 (print)/1890-9965 (electronic); 2018.
   Google Scholar
• Exchange rates. Oslo (Norway); 2022 [ accessed 2022 Mar 10]. https://www.norges-bank.no/en/topics/Statistics/exchange_rates/Internet.
   Google Scholar
• Norwegian Ministry of Health and Care Services. Principles for priority setting in health care - Summary of a white paper on priority setting in the Norwegian health care sector [Internet]. Oslo (Norway): Norwegian Government; 2016. https://www.regjeringen.no/contentassets/439a420e01914a18b21f351143ccc6af/en-gb/pdfs/stm201520160034000engpdfs.pdf.
   Google Scholar
• Norheim O, Allgott B, Gjul G, Kjellevold A, Moen A, Sjøli S. Norwegian [Transparent and fair – priorities in health services]. Oslo (Norway): Norwegian Government; 2014. https://www.regjeringen.no/no/dokumenter/NOU-2014-12/id2076730/?ch=1.
   Google Scholar
• Nymark LS, Miller A, Vassall A. Inclusion of additional unintended consequences in economic evaluation: a systematic review of immunization and tuberculosis cost-effectiveness analyses. Pharmacoecon Open. 2021;5(4):587–603. doi:10.1007/s41669-021-00269-4.
   PubMed Web of Science ®Google Scholar
• Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5. Value Health. 2012;15(6):828–834. doi:10.1016/j.jval.2012.06.011.
   PubMed Web of Science ®Google Scholar
• Nymark LS, Sharma T, Miller A, Enemark U, Griffiths UK. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Vaccine. 2017;35(49):6828–6841. doi:10.1016/j.vaccine.2017.10.024.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Goldblatt D. The duopoly of ten-valent and 13-valent pneumococcal conjugate vaccines: do they differ? Lancet Infect Dis. 2019;19(5):453–454. doi:10.1016/S1473-3099(18)30785-0.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O’-Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices—modeling studies. Value Health. 2003;6(1):9–17. doi:10.1046/j.1524-4733.2003.00234.x.
   PubMed Web of Science ®Google Scholar
• Immunisation and High Consequence Infectious Diseases Team, Global and Public Health Group. Consultation Ron the cost-effectiveness methodology for vaccination programmes and procurement (CEMIPP) report [Internet]; [accessed 2022 Mar 27]. https://www.gov.uk/government/consultations/cost-effectiveness-methodology-for-vaccination-programmes.
   Google Scholar